Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019

Abstract

AimsTo evaluate current status of prostate cancer incidence and mortality worldwide, and compare the global trends of incidence and mortality in the past two decades and in the most recent period.MethodsData on the incidence and mortality of prostate cancer for 174 countries in 2020 were obtained from the GLOBOCAN 2020 database, and associations with the human development index (HDI) were evaluated. Data for trend analyses in 89 countries from 2000 to 2019 were retrieved from the Global Burden of Disease 2019 platform. Age standardized incidence rate (ASIR) and mortality rate (ASMR) were calculated by using the Segi's population. The average annual percent changes (AAPC) of ASIRs and ASMRs were evaluated by joinpoint regression analysis.ResultsA total of 1 414 259 new cases of prostate cancer and 375 304 related deaths were reported in 2020 globally. HDI was positively correlated with ASIRs (P < 0.001) and negatively correlated with ASMRs (P < 0.001). In the past two decades, ASIRs have been increasing in 65 countries, stable in 15 countries and decreasing in 9 countries, and ASMRs have been increasing in 19 countries, stable in 25 countries and decreasing in 45 countries, respectively. In the most recent period, 44 countries have increasing ASIRs, and 32 countries have decreasing ASMRs, respectively. For instance, in the United States of America, the AAPC of ASIRs significantly decreased by 0.62% and ASMRs significantly decreased by 1.22% from 2000 to 2019, while the AAPC from 2015 to 2019 significantly increased by 0.49% for ASIRs and significantly increased by 0.48% for ASMRs.ConclusionThe magnitude of increasing incidence and decreasing mortality of prostate cancer is attenuated in the recent period. Further study is needed to analyze the absolute effect of risk factors, PSA screening and treatment.

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective

“…On the other hand, in Japan, the number of PCa cases was 106,139 with an age-standardized incidence rate of 51.8 per 100,000, and the number of deaths was 13,426 with an age-standardized mortality rate of 4.5 per 100,000. 12 Thus, morbidity and mortality rates in Japan are lower than those in the US, as race in addition to age and family history of PCa are well-known risk factors for PCa. In addition, total energy intake, obesity, and intake of dairy products have also been suggested as risk factors, which may affect different morbidity and mortality rates between the US and Japan.…”

Burden of All Cancers Along With Attributable Risk Factors in China From 1990 to 2019: Comparison With Japan, European Union, and USA

“…The age-standardized mortality rate of overall cancers in developed countries dropped gradually through decades of various efforts in cancer prevention and treatment ( 16 ). However, some common cancer types in developed countries, such as colorectal cancer, prostate cancer and breast cancer, have become common in China ( 17 – 20 ).…”

The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study

“…The prostate cancer is a prevalent cancer in male population 1 , with more than 1,400,000 new cases of prostate cancer and 370,000 related deaths were reported in 2020 globally 2 . About the treatment of ADT, the androgen deprivation therapy (ADT) has been used as a common therapy that can reduce the prostate function and suppress the progression of prostate cancer 1 , 3 , 4 .…”